ASX Announcements

Noxopharm provides update on NOX66 Clinical Trial Program
Idronoxil data provides hope to treat secondary brain cancer
NOX66 confirmed Non-Toxic. Trial Cleared for Full Enrolment
New Corporate Presentation
St Vincents Cancer Study to Commence-NOX66 and Radiotherapy
NOX makes strategic commitment to treatment of rare cancers
Noxopharm Mid Year Investor Briefings
Market Guidance for Next Six Months
Appendix 4C - quarterly
FNN Interview with NOX CEO Explaining Idronoxil-C Discovery